StockMarketWire.com - Genedrive said its antibiotic-induced hearing loss test kit had obtained CE marking paving the way for its NHS partners in Manchester and Liverpool to begin testing the product.

The Genedrive MT-RNR1 ID kit would be used in critical care settings to screen babies for a genetic mutation, which if present, can cause lifelong deafness when they were given certain antibiotics.

The company also said it would look to the opportunities outside of the UK where CE marking enabled market entry.


At 8:57am: [LON:GDR] Genedrive Plc share price was 0p at 18.5p



Story provided by StockMarketWire.com